Unlocking breakthrough orally delivered enzyme therapeutics engineered for rare, life-threatening diseases.
Unlocking breakthrough orally delivered enzyme therapeutics engineered for rare, life-threatening diseases.
breakthrough orally-delivered enzyme therapeutics
engineered for rare, life-threatening diseases.
breakthrough orally-delivered enzyme therapeutics
engineered for rare, life-threatening diseases.
Founded by people with a proven track record in cystic fibrosis and rare diseases — and driven by a single purpose: to make a meaningful difference for people living with rare diseases and their families and friends.
Founded by people with a proven track record in cystic fibrosis and rare diseases — and driven by a single purpose: to make a meaningful difference for people living with rare diseases and their families and friends.
learn moreWe are developing therapies for people with rare diseases, with a near-term focus on exocrine pancreatic insufficiency and cystic fibrosis —conditions that profoundly impact how people live, and have historically been poorly served by available treatments.
Anagram Therapeutics is focused on becoming the world's leading biopharmaceutical company developing breakthrough orally delivered enzymes for diseases that have a severe impact on the lives of infants, children, adults, and their families.
Our lead candidate, ANG003, is a novel broad-spectrum recombinant non-porcine enzyme replacement therapy currently in a Phase 2 clinical trial in people with cystic fibrosis and exocrine pancreatic insufficiency.
Through Anagram Therapeutics’ selective approach we are leveraging 25+ years of domain expertise in gastrointestinal diseases, novel enzyme stabilization technologies, and decades of experience to engineer breakthrough orally delivered therapeutics with the potential to transform how malabsorption syndromes and nutrient metabolism disorders are treated.
Together, we are working to meaningfully improve the lives of people living with malabsorption syndromes and nutrient metabolism disorders.
